SAPS-SLE (n=7) aPL+ SLE (n=4) Vascular PAPS (n=40) Obstetric PAPS (n=22)
Female, n (%) 5 (71%) 2 (50%) 27 (68%) 22 (100%)
Thrombosis 6 (85%) / 40/40 (100%) /
Obstetric manifestations 2 (29%) / 7 (17.5%) 22 (100%)
Positive LA 5 (72%) 2 (50%) 29 (73%) 18 (82%)
aCL IgG, GPL (median, IQR) 14 (12-106.5) 58 (27.5-91.25) 82 (46-103) 41 (5-75)
aCL IgM, MPL (median, IQR) 7 (3-8.5) 4 (0.75-7.25) 7 (2-16) 8 (2-17)
Anti-β2GPI IgG, OD (median, IQR) 0.67 (0.335-1.125) 0.985 (0.76-1.13) 1.24 (0.37-1.55) 0.49 (0.115-1.162)
Anti-β2GPI IgM, OD (median, IQR) 0.23 (0.17-0.43) 0.16 (0.095-1.2675) 0.25 (0.1-0.89) 0.13 (0.082-0.217)
Anti-D1, OD (median, IQR) 0.7 (0.4-2) 0.980 (0.373-1.541) 0.409 (0.212-0.74) 0.267 (0.191-0.493)
Anti-D4/5, OD (median, IQR) 0.25 (0.13-0.20) 0.226 (0.167-0.267) 0.233 (0.148-0.342) 0.151 (0.134-0.226)
Table 1: Demografic, clinical and laboratory characteristics of 73 subjects with positive anti-β2-glycoprotein I IgG antibodies.